Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534122 | 0.92 | CETP (0.84) | CETPL3MBTL1LMNAPOLB | |
| SCHEMBL13212562 | 0.86 | CETP (0.75) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL9746129 | 0.86 | CETP (0.75) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL1534061 | 0.86 | CETP (0.75) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL13212420 | 0.84 | CETP (0.73) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL12841121 | 0.84 | CETP (0.73) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL5706504 | 0.84 | CETP (0.71) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL23987377 | 0.82 | CETP (0.69) | CETPL3MBTL1KDM4ELMNAALOX12 | |
| SCHEMBL9574413 | 0.81 | CETP (0.69) | CETPL3MBTL1 | |
| SCHEMBL2301094 | 0.81 | CETP (0.68) | CETPL3MBTL1KDM4ELMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | claimed |
| US-8048452-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor | BEND RESEARCH, INC. (US) | 2011-11-01 | — | — | US | claimed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | claimed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | claimed |
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2008-01-31 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | claimed |
| US-20060211654-A1 | Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor | PFIZER PRODUCTS INC. | 2006-09-21 | — | — | US | claimed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | claimed |
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | claimed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | claimed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | claimed |
| JP-11222428-A | — | — | None | — | — | JP | disclosed |
| US-4853319-A | Photographic silver halide element and process | EASTMAN KODAK COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
| WO-1988004795-A1 | PHOTOGRAPHIC SILVER HALIDE ELEMENT AND PROCESS | EASTMAN KODAK COMPANY (US) | 1988-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | CETP, MTTP, APOB | CETP 1/4885L3MBTL1 1184/4885KDM4E 2520/4885 |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885L3MBTL1 832/4885KDM4E 2930/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885L3MBTL1 501/4885KDM4E 2364/4885 |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885L3MBTL1 3379/4885KDM4E 2729/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885L3MBTL1 4175/4885KDM4E 2545/4885 |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | CETP, PCSK9, LCAT | CETP 1/4885L3MBTL1 1808/4885KDM4E 1677/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885L3MBTL1 1449/4885KDM4E 3183/4885 |
| US-20060211654-A1 | Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor | CETP, HDLBP, MTTP | CETP 1/4885L3MBTL1 3246/4885KDM4E 2683/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885L3MBTL1 4163/4885KDM4E 2641/4885 |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885L3MBTL1 1480/4885KDM4E 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.